Targeted therapies: aiming for the bull's-eye.
Gaguski
Michele E
ME
Ocean Medical Center, Brick, NJ, USA.
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D002471:Cell Transformation, Neoplastic / Q000187:drug effects; D002986:Clinical Trials as Topic / Q000451:nursing; D016527:Drug Costs; D016503:Drug Delivery Systems / Q000191:economics / Q000379:methods* / Q000451:nursing*; D015195:Drug Design; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000209:etiology / Q000451:nursing; D024802:Nurse's Role; D009859:Oncology Nursing; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D066246:ErbB Receptors; D018719:Erb-b2 Receptor Tyrosine Kinases